Eli Lilly And Company ($LLY) announced an update on their ongoing clinical study. Study Overview: Eli Lilly and Company ...

Discover why Eli Lilly and Company's retatrutide weight loss breakthrough positions LLY as a leader in obesity therapeutics.

A novel triple receptor agonist conferred weight loss of up to 28.7% at 68 weeks and reductions in pain for adults with ...

Analysts were hoping for a safety profile similar to what was achieved in Phase II but an abnormal sense of touch, called ...

Retatrutide, originally developed by Eli Lilly, has found a loyal fan base—even though clinical trials of the drug still ...

Retatrutide, Eli Lilly’s triple-hormone obesity drug, delivers up to 28.7% weight loss and major knee pain relief in ...

A weight loss drug dubbed the "triple G" drug for its effectiveness in mimicking three hunger-regulating hormones showed ...

Step aside, semaglutide—retatrutide is showing the most impressive weight loss results of any obesity drug to date.

Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the Phase 3 TRIUMPH-4 clinical trial ...

Eli Lilly said on Thursday its next-generation obesity drug helped patients lose an average of 28.7% of their weight in a ...

The maker of Zepbound reported results from a study of retatrutide, which targets three hormones in the body and led to much more weight loss than any approved drug.

The clinical trial showed this experimental medication to be much more effective than any existing GLP-1 drug. But that much ...